BNTX:VIE
BioNTech SE - ADR
€84.65
arrow_downward
-0.24%(-0.20) 1D
Sep 9, 1:00:19 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
€85.10
High
€85.10
Low
€84.60
Mkt. cap
24.80B
Avg. vol.
278.00
Volume
0.00
52-wk high
€104.00
52-wk low
€68.65
No. of employees
8K
Open
€85.10
High
€85.10
Low
€84.60
Mkt. cap
24.80B
Avg. vol.
278.00
Volume
0.00
52-wk high
€104.00
52-wk low
€68.65
No. of employees
8K
News stories
From web sources and news partners
Kalkine Media
·
15 hours ago
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan
Simply Wall Street
·
16 hours ago
How Trial Termination At BioNTech (BNTX) Has Changed Its Investment Story
Yahoo Finance
·
1 day ago
BioNTech Shares Fall After BMO Downgrade and Price Target Cut
Investing.com South Africa
·
1 day ago
Why is BioNTech stock sliding today? By Investing.com
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR